Individualizing Glaucoma Treatment: Understanding How to Utilize Traditional and Novel Agents

This activity is supported by an unrestricted educational grant from Bausch + Lomb.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Describe the mechanisms of action of novel therapeutics and classes of drugs for ocular hypertension (OHT) and primary open angle glaucoma (POAG)
• Interpret the challenges and limitations associated with currently available pharmacologic treatment options for OHT and POAG
• Evaluate monotherapy and combination regimens and compare which option is most likely to achieve each individual patient’s goal IOP
• Compare and assess the efficacy of novel therapeutics with traditional prostaglandins

Accreditation and Designation Statement

This educational activity is provided by Evolve Medical Education LLC (Evolve).

Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsored by

Evolve is an approved COPE Administrator. 

This activity, COPE Activity Number 123003, is accredited by COPE for continuing education for optometrists. 
This course is approved for 1 hour of CE. 

Course # 75789-GL
Activity # 123003

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Nathan M. Radcliffe, MD, has had a financial agreement or affiliation during the past year with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alcon Laboratories, Alimera Sciences, Allergan, Bausch + Lomb, Beaver-Visitec International, Carl Zeiss Meditec, CATS, Ellex, ELT Sight, Equinox, Eyepoint, Glaukos Corporation, IRIDEX, Ivantis, Kala, Lumenis, New World Medical, Novartis Pharma AG, Ocular Science, Ocular Therapeutix, Omeros Corporation, Quantel Medical, Reichert, Santen, Shire, Sight Sciences, Spyglass, THEA, and ViaLase. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon Laboratories, Alimera Sciences, Allergan, Bausch + Lomb, Beaver-Visitec International, Eyepoint, Glaukos Corporation, IRIDEX, Ivantis, Kala, Lumenis, New World Medical, Novartis Pharma AG, Reichert, and Sight Sciences. Stock/Shareholder: CATS, ELT Sight, Equinox, Ivantis, Sight Sciences, and Spyglass.

Justin Schweitzer, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Dompé, EyePoint, Horizon, Ocular Therapeutix, and Reichert. Grant/Research Support: Glaukos. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, Quidel, Sight Sciences, and Sun Pharmaceutical Industries. Share/Stockholder: Equinox.

The Evolve staff and planners have no financial relationships with commercial interests.
Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch + Lomb.